HTBX News and Press, Heat Biologics Inc. From 03/03/21

Gainers: Ovid Therapeutics (OVID) +48%, KemPharm (KMPH) +46%, Ocugen (OCGN) +34%, Asensus Surgical (TRXC) +32%, Heat Biologics (HTBX) +16%.Losers: Vir Biotechnology (VIR) -29%, NanoViricides (NNVC) -16%, ASLAN Pharmaceutica...

Cantor Fitzgerald analyst Kristen Kluska has initiated shares of Heat Biologics, Inc. (HTBX) with an overweight rating and $22 price target.Kluska says that the company's proprietary T-cell activation immunotherapy platforms for oncology and infectious diseases has versatility in several soli...

Ovid Therapeutics (OVID) +73% after soticlestat deal with Takeda.KemPharm (KMPH) +69% on FDA approval of ADHD drug.Ocugen, Inc. (OCGN) +39% on Indian partner’s COVID-19 vaccine efficacy data.Asensus Surgical (TRXC) +33% on FDA clearance for Senhance Surgical System....

DURHAM, NC / ACCESSWIRE / February 12, 2021 / Heat Biologics, Inc. ("Heat") (Nasdaq:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, ...

Palm Beach, FL – February 10, 2021 – The incidence of cancer is increasing every year and it has been the major factor for the growth of the cancer vaccines market. Healthcare physicians are looking for alternate therapies, due to the huge burden of cancer cases and the side e...

Gainers: Applied UV (AUVI) +367%.Comstock Holding Companies (CHCI) +125%.KalVista Pharmaceuticals (KALV) +112%.Veru (VERU) +60%.Heat Biologics (HTBX) +58%.SemiLEDs (LEDS) +45%.U.S. Well Services (USWS) +41%.Tilray (TLRY) +41%.Eastside Distilling (EAST) +40%.FSD Pharma (HUGE) +35%.Lo...

Heat Biologics (HTBX) shares more than doubled in premarket trading after the company announces positive interim data from its Phase 2 trial of HS-110, in combination with Bristol-Myers Squibb's (BMY) OPDIVO (nivolumab) in advanced non-small cell lung cancer ((NSCLC)). HS-110 is an ...

KalVista Pharmaceuticals (KALV) +207% on reporting positive results for KVD900.Comstock Holding Companies (CHCI) +163%.Applied UV (AUVI) +88% after acquiring Airocide Technology Platform.Heat Biologics (HTBX) +47% on announcing positive interim survival data from ongoing HS-110...

Median overall survival of 24.6 months in previously treated checkpoint inhibitor naïve non-small cell lung cancer patients who received HS-110 in combination with nivolumab DURHAM, NC / ACCESSWIRE / February 9, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX) , a clinical-sta...

Heat Biologics (HTBX) has fallen ~10.7% in the premarket after the company announced that additional preclinical results of its COVID-19 vaccine candidate were published in Frontiers in Immunology, a peer-reviewed journal.Heat Biologics’ COVID-19 vaccine candid...